Vivos Therapeutics Net Income vs. Price To Book
| VVOS Stock | USD 2.06 0.16 7.21% |
Net Loss | First Reported 2019-03-31 | Previous Quarter -5 M | Current Value -5.4 M | Quarterly Volatility 4 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.76 | 0.69 |
|
|
For Vivos Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Vivos Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Vivos Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Vivos Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Vivos Therapeutics over time as well as its relative position and ranking within its peers.
Vivos Therapeutics' Revenue Breakdown by Earning Segment
Check out World Market Map.
Vivos Therapeutics Revenue Breakdown by Earning Segment
By analyzing Vivos Therapeutics' earnings estimates, investors can diagnose different trends across Vivos Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vivos Therapeutics. If investors know Vivos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vivos Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.77) | Revenue Per Share | Quarterly Revenue Growth 0.757 | Return On Assets | Return On Equity |
The market value of Vivos Therapeutics is measured differently than its book value, which is the value of Vivos that is recorded on the company's balance sheet. Investors also form their own opinion of Vivos Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vivos Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vivos Therapeutics' market value can be influenced by many factors that don't directly affect Vivos Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vivos Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vivos Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vivos Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Vivos Therapeutics Price To Book vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Vivos Therapeutics's current stock value. Our valuation model uses many indicators to compare Vivos Therapeutics value to that of its competitors to determine the firm's financial worth. Vivos Therapeutics is rated fourth in net income category among its peers. It is rated first in price to book category among its peers . At this time, Vivos Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Vivos Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Vivos Price To Book vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Vivos Therapeutics |
| = | (11.14 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Vivos Therapeutics |
| = | 7.55 X |
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Vivos Price To Book Comparison
Vivos Therapeutics is currently under evaluation in price to book category among its peers.
Vivos Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Vivos Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Vivos Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Vivos Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Vivos Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Interest Income | 134.6 K | 141.3 K | |
| Operating Income | -10.1 M | -10.6 M | |
| Net Loss | -10 M | -10.5 M | |
| Income Before Tax | -10 M | -10.5 M | |
| Total Other Income Expense Net | 40.2 K | 38.2 K | |
| Net Loss | -18.3 M | -19.2 M | |
| Net Loss | -10 M | -10.5 M | |
| Income Tax Expense | -1.1 M | -1.1 M | |
| Change To Netincome | 4.4 M | 3.7 M | |
| Net Loss | (2.00) | (2.10) | |
| Income Quality | 1.03 | 0.59 | |
| Net Income Per E B T | 1.15 | 1.11 |
Vivos Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Vivos Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Vivos Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Vivos Therapeutics' important profitability drivers and their relationship over time.
Vivos Therapeutics Earnings Estimation Breakdown
The calculation of Vivos Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Vivos Therapeutics is estimated to be -0.415 with the future projection ranging from a low of -0.45 to a high of -0.38. Please be aware that this consensus of annual earnings estimates for Vivos Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.45 Lowest | Expected EPS | -0.38 Highest |
Vivos Therapeutics Earnings Projection Consensus
Suppose the current estimates of Vivos Therapeutics' value are higher than the current market price of the Vivos Therapeutics stock. In this case, investors may conclude that Vivos Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Vivos Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 3 | 50.0% | 0.0 | -0.415 | -1.77 |
Vivos Therapeutics Earnings History
Earnings estimate consensus by Vivos Therapeutics analysts from Wall Street is used by the market to judge Vivos Therapeutics' stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Vivos Therapeutics' upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.Vivos Therapeutics Quarterly Gross Profit |
|
Vivos Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Vivos Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Vivos Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Vivos Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Vivos Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Vivos Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Vivos Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Vivos Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Vivos Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
2025-11-19 | 2025-09-30 | -0.48 | -0.49 | -0.01 | 2 | ||
2025-08-19 | 2025-06-30 | -0.39 | -0.55 | -0.16 | 41 | ||
2025-05-12 | 2025-03-31 | -0.4 | -0.48 | -0.08 | 20 | ||
2025-03-26 | 2024-12-31 | -0.43 | -0.28 | 0.15 | 34 | ||
2024-11-12 | 2024-09-30 | -0.61 | -0.4 | 0.21 | 34 | ||
2024-08-14 | 2024-06-30 | -1.05 | -0.6 | 0.45 | 42 | ||
2024-05-14 | 2024-03-31 | -1.17 | -1.63 | -0.46 | 39 | ||
2024-03-28 | 2023-12-31 | -1.9 | -3.05 | -1.15 | 60 | ||
2023-11-14 | 2023-09-30 | -3.12 | -1.62 | 1.5 | 48 | ||
2023-08-16 | 2023-06-30 | -0.14 | -0.18 | -0.04 | 28 | ||
2023-06-08 | 2023-03-31 | -0.18 | -0.07 | 0.11 | 61 | ||
2023-03-30 | 2022-12-31 | -0.22 | -0.2 | 0.02 | 9 | ||
2022-12-20 | 2022-09-30 | -0.28 | -0.33 | -0.05 | 17 | ||
2022-08-15 | 2022-06-30 | -0.25 | -0.28 | -0.03 | 12 | ||
2022-05-16 | 2022-03-31 | -0.26 | -0.26 | 0.0 | 0 | ||
2022-03-31 | 2021-12-31 | -0.25 | -0.34 | -0.09 | 36 | ||
2021-11-15 | 2021-09-30 | -0.18 | -0.26 | -0.08 | 44 | ||
2021-08-12 | 2021-06-30 | -0.18 | -0.19 | -0.01 | 5 | ||
2021-05-17 | 2021-03-31 | -0.17 | -0.19 | -0.02 | 11 | ||
2021-03-25 | 2020-12-31 | -0.16 | -0.88 | -0.72 | 450 | ||
2020-12-14 | 2020-09-30 | 0 | -0.23 | -0.23 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.1636 | -0.1636 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.1793 | -0.1793 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.1793 | -0.1793 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -0.2697 | -0.2697 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.2259 | -0.2259 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.2259 | -0.2259 | 0 |
Use Vivos Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Vivos Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Vivos Therapeutics will appreciate offsetting losses from the drop in the long position's value.Vivos Therapeutics Pair Trading
Vivos Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Vivos Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Vivos Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Vivos Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Vivos Therapeutics to buy it.
The correlation of Vivos Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Vivos Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Vivos Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Vivos Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Vivos Therapeutics position
In addition to having Vivos Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Picks Thematic Idea Now
Macroaxis Picks
Daily selected watch list of stocks of large companies handpicked by Macroaxis Team based on their diversification potential. The Macroaxis Picks theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Picks Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.